SITE014-0082

SITE014 (NLD) › SITE014-0082

SITE014-0082

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2025-11-29

enrolled

AEs

3

Serious

0

Dropout signal

–

Adverse events

3

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-02 (study day 177); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-13 (study day 127); relationship: NOT RELATED

mild assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-08-18 (study day 71); relationship: RELATED

moderate assessed

Data queries

0

No data queries. Open queries would appear here for this patient.